Earnings History Data for Cyclacel Pharmaceuticals, Inc. (CYCC) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Cyclacel Pharmaceuticals, Inc.
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14-08-2024 | PM | CYCC | Cyclacel Pharmaceuticals, Inc. | 2.08 | -0.72 | -0.83 | -6.60 | Cyclacel Pharmaceuticals GAAP EPS of -$0.72 [8/15/2024 8:55 AM] |
1.32 | -0.13 (-8.97%) |
1.43 | -0.02 (-1.38%) |
1.23 - 11.34 | 593,843 | 50,000 | 1,670 | ||
| 14-05-2024 | AH | CYCC | Cyclacel Pharmaceuticals, Inc. | 2.99 | -2.27 | -4.93 | -7.05 | Cyclacel Pharmaceuticals GAAP EPS of -$2.27 beats by $2.48 [5/14/2024 4:53 PM] |
2.48 | -0.36 (-12.82%) |
2.70 | -0.14 (-4.93%) |
1.30 - 13.20 | 157,974 | 2,170,000 | 3,137 | ||
| 19-03-2024 | AH | CYCC | Cyclacel Pharmaceuticals, Inc. | 2.05 | -6.23 | -6.35 | 9.00 | Cyclacel Pharmaceuticals GAAP EPS of -$6.23 misses by $0.34 [3/19/2024 4:15 PM] |
2.25 | -0.10 (-4.26%) |
2.49 | 0.14 (5.96%) |
2.00 - 13.20 | 48,675 | 30,000 | 324 | ||
| 13-11-2023 | PM | CYCC | Cyclacel Pharmaceuticals, Inc. | 7.33 | -0.49 | -0.38 | -0.42 | Cyclacel Pharmaceuticals GAAP EPS of -$0.49 misses by $0.13, revenue of $0.02M [11/14/2023 9:59 AM] |
0.3251 | -0.20 (-37.54%) |
0.51 | -0.01 (-2.38%) |
0.28 - 1.23 | 515,856 | 90,000 | 235 | ||
| 09-08-2023 | AH | CYCC | Cyclacel Pharmaceuticals, Inc. | 7.42 | -0.44 | -0.54 | -0.46 | Cyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37M [8/9/2023 4:49 PM] |
0.5570 | 0.0 (0.91%) |
0.60 | 0.05 (8.70%) |
0.50 - 2.41 | 74,907 | 50,000 | 3,290 | ||
| 11-05-2023 | AH | 4:05 PM ET (May 11) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 7.12 | -0.47 | -0.68 | -0.42 | Cyclacel Pharmaceuticals GAAP EPS of -$0.47 beats by $0.19 [5/11/2023 4:49 PM] |
0.5504 | -0.01 (-1.24%) |
0.58 | 0.02 (2.98%) |
0.50 - 2.41 | 30,070 | 70,000 | 575 | |
| 06-03-2023 | AH | 4:05 PM ET (Mar 6) |
CYCC | Cyclacel Pharmaceuticals | 10.00 | -0.60 | -0.53 | 0.00 | Cyclacel Pharmaceuticals GAAP EPS of -$0.60 misses by $0.12 [3/6/2023 4:20 PM] |
0.7047 | -0.04 (-5.85%) |
0.71 | -0.04 (-4.89%) |
0.53 - 3.55 | 71,949 | 70,000 | 3,215 | |
| 09-11-2022 | AH | 4:05 PM ET (Nov 9) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 15.80 | -0.42 | -0.55 | -0.54 | Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.14 [11/9/2022 4:21 PM] |
1.16 | -0.02 (-1.69%) |
0.0 | 0.0 (0.00%) |
1.01 - 5.59 | 67,637 | 110,000 | 0 | |
| 10-08-2022 | AH | 4:05 PM ET (Aug 10) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 13.19 | -0.46 | -0.67 | -0.56 | Cyclacel Pharmaceuticals GAAP EPS of -$0.46 beats by $0.08, revenue of $0M [8/10/2022 5:53 PM] |
1.70 | 0.37 (27.82%) |
1.49 | 0.16 (12.03%) |
1.01 - 6.10 | 7,604,024 | 850,000 | 1,974,787 | |
| 11-05-2022 | AH | 4:05 PM ET (May 11) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 14.69 | -0.42 | -0.67 | -0.50 | Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.27 [5/11/2022 4:16 PM] |
1.38 | 0.06 (4.70%) |
1.32 | 0.0 (0.00%) |
1.29 - 7.95 | 45,006 | 60,000 | 550 | |
| 28-03-2022 | AH | 4:05 PM ET (Mar 28) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 31.62 | -0.54 | -0.71 | -1.34 | Cyclacel Pharmaceuticals GAAP EPS of -$1.34 [3/28/2022 4:34 PM] |
3.24 | 0.09 (2.86%) |
3.30 | 0.15 (4.76%) |
2.63 - 7.95 | 22,118 | 30,000 | 1,000 | |
| 10-11-2021 | AH | 4:05 PM ET (Nov 10) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 45.80 | -0.54 | -0.70 | -0.47 | Cyclacel Pharmaceuticals EPS beats by $0.23 [11/10/2021 4:41 PM] |
4.99 | -0.11 (-2.16%) |
5.02 | -0.08 (-1.57%) |
3.34 - 11.42 | 76,544 | 60,000 | 415 | |
| 11-08-2021 | AH | 4:05 PM ET (Aug 11) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 47.93 | -0.56 | -0.47 | -0.58 | Cyclacel Pharmaceuticals EPS misses by $0.07 [8/11/2021 4:23 PM] |
5.05 | -0.17 (-3.26%) |
5.20 | -0.02 (-0.38%) |
3.12 - 11.42 | 66,748 | 60,000 | 180 | |
| 12-05-2021 | AH | 4:05 PM ET (May 12) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 61.04 | -0.50 | -0.45 | -1.48 | Cyclacel Pharmaceuticals EPS misses by $0.99 [5/12/2021 4:28 PM] |
6.65 | 0.28 (4.40%) |
6.90 | 0.53 (8.32%) |
3.12 - 11.42 | 114,023 | 220,000 | 1,009 | |
| 25-02-2021 | AH | 4:05 PM ET (Feb 25) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 35.31 | -1.34 | -0.51 | -2.80 | Cyclacel Pharmaceuticals EPS misses by $2.21 [2/25/2021 5:04 PM] |
6.91 | -0.09 (-1.29%) |
6.95 | -0.05 (-0.71%) |
3.12 - 19.25 | 383,310 | 653,643 | 4,829 | |
| 11-11-2020 | AH | 4:05 PM ET (Nov 11) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 16.20 | -0.47 | -0.49 | -2.20 | Cyclacel Pharmaceuticals EPS misses by $1.74 [11/11/2020 4:14 PM] |
3.46 | -0.05 (-1.42%) |
3.50 | -0.01 (-0.28%) |
3.12 - 19.60 | 43,871 | 47,839 | 419 | |
|
|
||||||||||||||||||
| 12-08-2020 | AH | 4:05 PM ET (Aug 12) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 23.86 | -0.58 | -0.47 | -3.20 | Cyclacel Pharmaceuticals EPS misses by $1.66 [8/12/2020 4:19 PM] |
4.27 | -0.29 (-6.36%) |
4.25 | -0.31 (-6.80%) |
3.85 - 19.60 | 287,139 | 488,873 | 7,697 | |
|
|
||||||||||||||||||
| 12-05-2020 | AH | 4:05 PM ET (May 12) |
CYCC | Cyclacel Pharmaceuticals, Inc. | 11.41 | -1.48 | -2.80 | 3.00 | Cyclacel Pharmaceuticals EPS beats by $0.13 [5/12/2020 4:09 PM] |
4.22 | 0.09 (2.18%) |
4.18 | -0.04 (-0.95%) |
3.85 - 20.40 | 5,562,360 | 632,426 | 20,486 | |
|
|
||||||||||||||||||